
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is primed for success with its strong pipeline and strategic collaborations, such as the recent $200M opt-out fee from Takeda and potential milestone payments from its partners. With a strong cash balance of $620M and a projected runway into at least 2028, the company is well-positioned to continue developing its lead candidate, rusfertide, for polycythemia vera, while also exploring other promising programs in its pipeline. Furthermore, Protagonist's success with its partnered programs, such as Icotyde's projected peak sales of over $10B, highlights the potential for the company's proprietary technology platform and positions it for continued stock outperformance.
Bears say
Protagonist Therapeutics is facing potential dilution in their shares, which is reflected in their recent 10-Q filing. Despite this, their potential approval for rusfertide in polycythemia vera and partnerships in their pipeline may lead to short-term profitability. However, with no current products on the market and uncertainty in pipeline development, their long-term financial stability remains questionable.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares